Fred Aslan is listed as an executive officer and director on 2 SEC Form D filings by 2 issuers between May 2019 and Apr 2021: Vividion Therapeutics, Inc. (San Diego, CA — biotechnology — 2019; $135M reported sold to 27 investors) and Artiva Biotherapeutics, Inc. (San Diego, CA — biotechnology — 2021; $120M reported sold to 27 investors).
What this means 2 separate companies raised money with this person listed as executive officer and director, over about 2 years. Across those companies the filings report $255M sold in total.
Listed alongside Benjamin Cravatt (1 shared filing), Bong Koh (1 shared filing), Brian Daniels (1 shared filing), Diego K. Miralles (1 shared filing), Esther van den Boom (1 shared filing) and 14 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Fred. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Fred Aslan and found 4 differences: Form D filed 42 days after the first sale; Same name, different state: "FRED ASLAN, MD" (MA) is a separate record; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.